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ABSTRACT 
Many  factors  play  a  role  in  Acute  Myocardial  Infarction  (AMI).  One  those  anti-Phospholipid  (aPL) 
antibodies, that may act in the induction of immunological response leading to the development of AMI. 
Anti-Phosphatidylcholines  (PC)  antibody  is  detected  in  various  diseases  like  rheumatoid  arthritis, 
systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-PC antibody 
in AMI might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. 
This study was designed to investigate whether prevalence of anti-PC antibodies, in patients who had 
AMI and to analyze their relationship with traditional cardiovascular risk factors. The prevalence of 
anti-PC IgG and IgM in a well characterized group of patients with AMI as a case group and in age 
and sex matched healthy subjects as control group. Sera from the case and the control groups were 
tested to evaluate the presence of IgG and IgM isotypes to anti-PC by ELISA method. The prevalence 
of anti-PC IgG and also IgM in the case group resulted significantly higher than in the control group 
with  AMI  (p<0.005).  Our  findings  suggest  that  anti-PC  antibodies  seemed  to  play  a  role  in  AMI, 
independent  risk  factors  for  AMI,  which  may  represent  a  link  between  autoimmunity  and 
atherosclerosis in patients with AMI. Further studies with bigger sample size including patients with 
AMI and healthy people are needed to explore the exact role of anti-PC antibodies in AMI. 
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1. INTRODUCTION 
Antiphospholipid  antibodies  (aPL)  in  addition  to 
repeated  miscarriages  and  pregnancy  complications 
(Jahromi et al., 2010a) are associated with cardiovascular 
diseases  (Jahromi  et  al.,  2013;  Shojaie  and  Jahromi, 
2011; Jafarzadeh et al., 2011). However their pathogenic 
mechanisms are still matter of investigation. 
In  addition  to  the  Classical  Lupus  Anticoagulant 
(LAC)  and  Anti-Cardiolipin  Antibodies  (ACA),  other 
anti-Phospholipid Antibodies (aPL) were shown to target 
anionic  phospholipids  and  other  plasma  proteins, 
including  phosphatidylethanolamine,  protein  C,  protein 
S,  ß2-Glycoprotein  I  (beta2-gpI)  and  annexin  V   
(Tincani et al., 2010). Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 116-119, 2013 
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Myocardial Infarction (MI) is the combined result of 
environmental  factors  and  personal  predispositions. 
Factors such as low serum adiponectin (Shojaie et al., 
2009a) and low annexin V levels (Shojaie et al., 2009b) 
and infectious diseases such as Mycoplasma pneumonia 
(Pourahmad et al., 2009) are a part of involving factors 
in  AMI.  It  has  been  demonstrated  that  the 
immunopathological  such  as  anti-beta2  glycoprotein-I 
antibody (Shojaie and Jahromi, 2011) and Inflammatory 
processes (Jahromi et al., 2010a) play important roles in 
the initiation and development of AMI. 
The  results  of  some  studies  also  demonstrated  an 
association between anti-PL antibody and IHD (Shojaie 
and Jahromi, 2011; Jafarzadeh et al., 2011). It should be 
noted that genetic factors as well as other traditional risk 
factors such as smoking, hypercholesterolemia, diabetes 
mellitus  and  hypertension  may  contribute  to  IHD 
development and these parameters differ among various 
population.  Although  there  are  a  few  studies  on  the 
association  of  some  autoantibodies  with  AMI,  more 
epidemiological  data  are  required  to  confirm  their 
significance as independent risk factors in cardiovascular 
diseases.  Moreover,  the  data  on  the  relationship  of 
autoantibodies  with  traditional  risk  factors  of  AMI  is 
scarce. Therefore, this study was conducted to evaluate 
the  serum  levels  of  Anti-Phosphatidylcholines  (PC) 
antibodies (IgG and IgM) in Iranian patients with AMI 
and also to clarify their association with traditional risk 
factors of the disease.  
2. MATERIALS AND METHODS 
2.1. Subjects 
A  total  of  90  consecutive  patients  (aged  41-67 
years)  with  AMI  including  67  men  and  23  women 
who were admitted to Peymanieh Hospital of Jahrom 
in  southwest  of  Iran,  were  enrolled  to  this  cross-
sectional, case-control study. 
AMI  was diagnosed by the presence of two of the 
following  criteria:  (i)  prolonged  chest  pain  compatible 
with  AMI,  (ii)  typical  ECG  changes,  (iii)  rising  of 
cardiac  enzymes  such  as  creatine  kinase  and  lactate 
dehydrogenase.  UA  was  defined  according  to  the 
Braunwald’s classification and all patients had chest pain 
at  rest  with  definite  ischemic  electrocardiographic 
changes  such  as  ST-segment  changes  and/or  T-wave 
inversion (Antman et al., 2008). 
Exclusion  criteria  were  valvular  heart  disease, 
surgery, trauma during the prior month, cardiomyopathy, 
liver disease, renal failure, arthritis, malignant diseases, 
other inflammatory diseases (such as SLE and RA) and 
oral  anticoagulant  therapy.  In  patients  with  AMI,  the 
serum  concentration  of  Anti-PC  antibodies  was 
measured during 3-5 days after admission.  
A  age,  sex  and  other  CAD  risk  factors  such  as 
Hypertension (HTN), Diabetes Mellitus (DM) and Hyper 
Lipidemia (HLP) matched group (n = 90) with similar 
geographic and socioeconomic backgrounds without any 
ischemic heart disease were used as a control group. All 
control subjects were basically healthy, with no acute or 
chronic illnesses and did not use any drugs. The healthy 
control group was recruited from blood donors attending 
Jahrom Blood Transfusion Center. Peripheral blood (3 
milliliter)  was  collected  from  the  two  groups  and  the 
serum was separated and stored at -20°C.  
The study protocol was approved by research ethics 
committee  of  Jahrom  University  of  Medical  Sciences 
and  informed  consents  were  obtained  from  all 
participants before enrollment. 
The  patient  or  his  legal  representative  provided 
written  informed  consent.  Historical,  demographic  and 
clinical data were obtained through a review of medical 
records and interviews with patients and their families. 
The  risk  factors  for  myocardial  infarction  were  as 
follows:  (1)  age,  sex;  (2)  history  of  hypertension 
(diagnosis  confirmed  when  the  systolic  or  diastolic 
pressures were > 160 or 95 mmHg, respectively, or when 
the patient was using antihypertensive medication) 12; (3) 
smoking, according to the criteria of the British Council 
for Medical Research; (4) history of heart disease (atrial 
fibrillation or coronary heart disease, defined as previous 
myocardial  infarction,  angina,  or  revascularization 
procedure); (5) history of diabetes mellitus, according to 
the medical history or the use of insulin or an oral anti-
diabetes  drug;  (6)  hypercholesterolemia,  based  on  total 
cholesterol  >200  mg  dL
-1,  LDL-cholesterol  >130  mg 
dL
-1,  or  total  cholesterol/HDL-cholesterol  ratio  >5 
(Donahue et al., 1988). 
Blood samples (5 cc) were obtained by venipuncture 
from  the  patients  immediately  after  admission  before 
starting any IV medications by skilled personnel. Blood 
samples were centrifuged and frozen within, at most, 2 h 
after  collection  and  stored  at  -20°C  until  laboratory 
testing with ELISA. Serum anti-PC IgG and anti-PC IgM 
levels  was  determined  by  quantitative  and  qualitative 
ELISA method respectively, following the manufacturer 
instructions using IBL company, REF: RE70461. 
Statistical analyses were performed by SPSS (version 
17;  SPSS,  Inc.,  Chicago,  IL).  Data  were  expressed  as 
mean  ±  SD.  Continuous  variables  with  little-to-mild 
skewness were summarized as mean ± SD and compared 
using Student’s t-test. Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 116-119, 2013 
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Table 1. Demographic, clinical characteristics and laboratory finding for the case and the control groups 
Variables  Patients group  Control group  P-value 
Age (year)  9.63±62.66  10.63±60.53  0.609 
Male (%) numbers  67(74.40%)  68 (75.60%)  0.863 
High blood pressure (%) numbers  39 (43.33%)  28 (31.10%)  0.079 
Smoker (%) numbers  40 (44.40%)  32 (35.60%)  0.287 
IDDM * (%) numbers  24 (26.70%)  28 (31.10%)  0.622 
Total cholesterol * Mg/dL  176.13±40.30  168.80±43.20  0.104 
HDL-C * Mg/dL  44.20±9.11  42.83±10.29  0.328 
LDL-C * Mg/dL  118.05±36.32  98.22±30.64  0.093 
TG * Mg/dL  126.53±72.18  114.84±41.52  0.104 
FBS * Mg/dL  134.20±54.48  127.08±53.91  0.495 
Positive Anti-Phosphatidylcholine IgG  27 (30.00%)  10 (11.10%)  0.002 
Positive Anti-Phosphatidylcholine IgM (%) numbers  15 (16.70%)  (3.30%) 3  0.003 
*IDDM = Insuline Dependent Diabetes Mellitus, NIDDM = Non-Insuline Dependent Diabetes Mellitus, HDL-C = High Density 
Lipoprotein-Cholesterol, LDL-C = Low Density Lipoprotein-Cholesterol, FBS = Fasting Blood Sugar 
 
3. RESULTS 
The demographic and clinical characteristics of the 
study  groups,  as  well  as  laboratory  variables  are 
shown in Table 1. 
In the patient group 16 cases (18.80%) had Non-St 
Elevation  MI  (NSTEMI)  and  74  (82.20%)  had  ST 
Elevation MI (STEMI). 
There was no significant difference between the two 
groups regarding the following variables: age, sex, HTN, 
DM, LDL, HDL, total cholesterol and TG. 
We examined the association between positive anti-
PC IgG and IgM tests and selected cardiovascular risk 
factors.  There  was  a  significant  association  between 
positive  anti-PC  IgG  and  IgM  tests  with  Type 
hypertension.  But  there  was  not  found  any  significant 
association between positive anti-PC IgG and IgM test 
with Type 1 DM, Type 2 DM, age, sex, LDL, HDL, TG, 
total cholesterol and adjusted smoking. 
There was not found significant difference between 
positive anti-PC IgG tests in patients with STEMI and 
those with NSTEMI (73.30% Vs 25.90%), (p = 0.186) 
and  also  there  was  not  found  significant  difference 
between  positive  anti-PC  IgM  tests  in  patients  with 
STEMI and those with NSTEMI (74.10% Vs 26.70%), 
(p = 0.324). 
4. DISCUSSION 
The  results  of  the  present  study  showed  that  the 
prevalence  of  positive  anti-PC  IgG  and  also  IgM 
antibodies in patients with AMI were significantly higher 
than  that  observed  in  healthy  control  group.  These 
associations were independent of traditional risk factors. 
We  found  high  prevalence  of  anti-PC  antibodies  in 
patients with AMI Vs healthy control group consistent 
with  current  concepts  on  the  immune  pathogenesis  of 
atherosclerosis.  However,  the  precise  mechanisms  of 
involvement of anti-PC antibodies in the pathogenesis of 
AMI remain to be determined. 
We could not find any research finding about anti-PC 
antibodies in AMI to compare its results with the results 
of present study. 
Other aPLs  have been reported to have association 
with  CAD  and  AMI  (Shojaie  and  Jahromi,  2011; 
Jafarzadeh et al., 2011; Greco et al., 2010). 
There was not found correlation between anti-PC IgG 
and  also  IgM  and  standard  cardiovascular  risk  factors 
such  as  smoking,  hypertension  and  diabetes,  as  seen 
about other apl antibodies in a previous study (Shojaie 
and Jahromi, 2011; Jahromi et al., 2010b). 
In  this  study  there  was  a  significant  association 
between  anti-PC  IgG  with  HTN  in  the  case  and  the 
control groups. The same results were found about anti-
β2GPI  IgG  in  AMI  in  other  studies  (Yamada  et  al., 
2010).  These  results  suggest  that  anti-β2GPI  IgG  is 
independent of these variables. 
As  there  were  not  significant  differences  between 
positive anti-PC antibodies test in patients with STEMI 
and those with NSTEMI, it can be concluded that anti-
PC  IgG  and  IgM  do  not  participate  in  kind  of  AMI 
(STEMI vs NSTEMI). But, unfortunately we did not any 
data indicating association of anti-PC IgG and IgM with 
these parameters to compare the results. 
5. CONCLUSION 
These  results  show  an  association  between  AMI 
and high prevalence of positive tests for anti-PC IgG 
and IgM. The results of this study in parallel with the Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 116-119, 2013 
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data  from  other  studies (Shojaie and Jahromi, 2011; 
Jafarzadeh et al., 2011; Greco et al., 2009; Urbanus et al., 
2009)  support  the  potential  important  role  of  aPL 
antibodies in AMI. 
Further studies with larger sample size of patients and 
healthy subjects are recommended to explore the precise 
role of anti-PC IgG and IgM in AMI. 
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